RESUMO
We aim to assess the relationship between validated smoking cessation pharmacotherapies and electronic cigarettes (e-cigarettes) and insomnia and parasomnia using a systematic review and a network meta-analysis. A systematic search was performed until August 2022 in the following databases: PUBMED, COCHRANE, CLINICALTRIAL. Randomized controlled studies against placebo or validated therapeutic smoking cessation methods and e-cigarettes in adult smokers without unstable or psychiatric comorbidity were included. The primary outcome was the presence of "insomnia" and "parasomnia." A total of 1261 studies were selected. Thirty-seven studies were included in the quantitative analysis (34 for insomnia and 23 for parasomnia). The reported interventions were varenicline (23 studies), nicotine replacement therapy (NRT, 10 studies), bupropion (15 studies). No studies on e-cigarettes were included. Bayesian analyses found that insomnia and parasomnia are more frequent with smoking cessation therapies than placebo except for bupropion. Insomnia was less frequent with nicotine substitutes but more frequent with bupropion than the over pharmacotherapies. Parasomnia are less frequent with bupropion but more frequent with varenicline than the over pharmacotherapies. Validated smoking cessation pharmacotherapies can induce sleep disturbances with different degrees of frequency. Our network meta-analysis shows a more favorable profile of nicotine substitutes for insomnia and bupropion for parasomnia. It seems essential to systematize the assessment of sleep disturbances in the initiation of smoking cessation treatment. This could help professionals to personalize the choice of treatment according to sleep parameters of each patient. Considering co-addictions, broadening the populations studied and standardizing the measurement are additional avenues for future research.
Assuntos
Sistemas Eletrônicos de Liberação de Nicotina , Metanálise em Rede , Parassonias , Distúrbios do Início e da Manutenção do Sono , Abandono do Hábito de Fumar , Humanos , Abandono do Hábito de Fumar/métodos , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Parassonias/induzido quimicamente , Agentes de Cessação do Hábito de Fumar/uso terapêutico , Agentes de Cessação do Hábito de Fumar/efeitos adversos , Dispositivos para o Abandono do Uso de Tabaco , Vareniclina/uso terapêutico , Vareniclina/efeitos adversos , Bupropiona/uso terapêutico , Bupropiona/efeitos adversosRESUMO
BACKGROUND: Sleep walking (SW) is a parasomnia behavior characterized by repetitious occurrence of ambulation during a partial arousal from non-rapid eye movement (NREM) sleep. Sleep-related eating (SRE) is one of the complex sleep behaviors that may accompany SW. Emerging evidence suggests that NREM parasomnias can be associated with atypical antipsychotic medication use. METHODS: We present a case series (nâ¯=â¯5) and a systematic review of the literature of cases of SW, with or without SRE (nâ¯=â¯23), associated with atypical antipsychotic use. RESULTS: Twenty-eight cases of SW, with and without SRE, with a mean age of 44.8â¯years (S.D. = 15.04) and a male predominance (75%; nâ¯=â¯21) were identified. Quetiapine was the most commonly implicated medication with SW and SRE (nâ¯=â¯14). Remission from SW/SRE was noted in all cases with measures including antipsychotic dosage reduction, discontinuation of medication, switching to an alternate medication, and use of continuous positive airway pressure (CPAP) for comorbid obstructive sleep apnea (OSA) treatment. CONCLUSIONS: Sleep walking (SW), with or without sleep related eating (SRE), can be a rare but reversible side effect associated with use of atypical antipsychotics. More research is warranted to elucidate the mechanisms underlying SW and SRE associated with atypical antipsychotic use.
Assuntos
Antipsicóticos/efeitos adversos , Comportamento Alimentar/efeitos dos fármacos , Parassonias/induzido quimicamente , Fumarato de Quetiapina/efeitos adversos , Sonambulismo/induzido quimicamente , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto JovemRESUMO
PURPOSE: To identify and analyze postmarketing cases of complex sleep behaviors (CSBs) resulting in serious injuries, including death, associated with eszopiclone, zaleplon, or zolpidem (Z-drugs). METHODS: Retrospective analysis of the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from 16 December 1992 through 27 February 2018 and medical literature using PubMed and EMBASE. We used random sampling and descriptive statistics. RESULTS: We identified 66 cases that met inclusion and exclusion criteria, four of which were identified in the medical literature. Twenty cases reported death and 46 cases reported serious injuries in association with CSBs occurring after the use of a Z-drug. Fatal cases described events, such as carbon monoxide poisoning, drowning, falls, hypothermia, motor vehicle collisions, and apparent completed suicide. Nonfatal cases resulting in serious injuries described events, such as accidental overdoses, falls, gunshot wounds, hypothermia, third-degree burns, and self-injuries or suicide attempts. Twenty-two cases reported a previous episode of a CSB while taking a Z-drug prior to the event reported in this case series. CONCLUSIONS: The FAERS and medical literature cases support the need for increased awareness of the consequences that may occur because of CSBs associated with the use of Z-drugs. Therefore, to protect public health, regulatory actions were taken, including adding a Boxed Warning, a Contraindication in patients who have experienced a prior episode of a CSB with a Z-drug, and updating the existing Warnings and Precautions. An FDA Drug Safety Communication was also disseminated to alert healthcare professionals and the public of this potential risk.
Assuntos
Acetamidas/efeitos adversos , Zopiclona/efeitos adversos , Parassonias/induzido quimicamente , Pirimidinas/efeitos adversos , Medicamentos Indutores do Sono/efeitos adversos , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Sono/efeitos dos fármacos , Ferimentos e Lesões/induzido quimicamente , Zolpidem/efeitos adversos , Adulto , Sistemas de Notificação de Reações Adversas a Medicamentos , Idoso , Rotulagem de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Parassonias/mortalidade , Parassonias/fisiopatologia , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Distúrbios do Início e da Manutenção do Sono/diagnóstico , Distúrbios do Início e da Manutenção do Sono/fisiopatologia , Sonambulismo/induzido quimicamente , Sonambulismo/mortalidade , Sonambulismo/fisiopatologia , Fatores de Tempo , Resultado do Tratamento , Ferimentos e Lesões/mortalidade , Ferimentos e Lesões/fisiopatologiaRESUMO
Sleep-related eating disorder (SRED) is characterized by recurrent episodes of eating during the night, accompanied by partial consciousness and followed by limited recall. Zolpidem is a sedative-hypnotic drug commonly used to treat sleep disorders. Zolpidem reduces sleep latency and increases the total time of sleep. Here, we described a case of a patient with attention-deficit/hyperactivity disorder (ADHD) who suffered from zolpidem-induced SRED. The symptoms disappeared when the use of zolpidem as discontinuation. To the best of our knowledge, this is the first documented case of SRED induced by the use of zolpidem in a patient with ADHD.
Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Transtornos da Alimentação e da Ingestão de Alimentos/induzido quimicamente , Parassonias/induzido quimicamente , Medicamentos Indutores do Sono/efeitos adversos , Zolpidem/efeitos adversos , Adulto , Feminino , Humanos , Adulto JovemAssuntos
Agonistas de Dopamina/efeitos adversos , Parassonias/induzido quimicamente , Polissonografia/métodos , Pramipexol/efeitos adversos , Nível de Alerta/efeitos dos fármacos , Agonistas de Dopamina/uso terapêutico , Feminino , Humanos , Pessoa de Meia-Idade , Parassonias/diagnóstico , Pramipexol/uso terapêutico , Síndrome das Pernas Inquietas/tratamento farmacológico , Transtornos do Despertar do Sono/induzido quimicamenteRESUMO
ABSTRACT: The most common sleep disorders that can result in injurious or violent behaviors include REM sleep behavioral disorder, sleepwalking, comorbid parasomnias, sleep-related dissociative disorder, and obstructive sleep apnea. Video polysomnography is usually indicated to evaluate recurring sleep-related injury in adults. Only one-third of patients with complex paroxysmal nocturnal events will have one of their habitual events on a single night of in-laboratory video polysomnography, most often those who have prominent, high-frequency motor features. We report evidence of sleep walking induced by sodium oxybate identified by steps recorded on a consumer wearable device coinciding with clinical history and evidence of injury.
Assuntos
Polissonografia , Oxibato de Sódio/efeitos adversos , Sonambulismo/induzido quimicamente , Gravação em Vídeo , Adulto , Distúrbios do Sono por Sonolência Excessiva/diagnóstico , Desenho de Equipamento , Feminino , Humanos , Narcolepsia/diagnóstico , Parassonias/induzido quimicamente , Parassonias/diagnóstico , Polissonografia/instrumentação , Oxibato de Sódio/uso terapêutico , Sonambulismo/diagnósticoRESUMO
Sleep-related eating disorder (SRED) is classified within parasomnia and is characterised by recurrent episodes of abnormal, dysfunctional eating during sleep. This report describes a case of SRED in a 19-year-old woman admitted to the psychiatric ward with worsening anxiety, low mood and suicidal ideation. She was started on low-dose mirtazapine for mood stabilisation and, following an incremental increase to 30 mg, she developed nocturnal binge eating of which she retained only partial memory on waking. She developed adverse health consequences as a result of these recurrent episodes. The subject's symptoms were relieved rapidly following reduction of the dose of mirtazapine back to 15 mg.
Assuntos
Antidepressivos/efeitos adversos , Transtorno Depressivo/tratamento farmacológico , Transtornos da Alimentação e da Ingestão de Alimentos/diagnóstico , Mirtazapina/efeitos adversos , Parassonias/diagnóstico , Diagnóstico Diferencial , Transtornos da Alimentação e da Ingestão de Alimentos/induzido quimicamente , Feminino , Humanos , Parassonias/induzido quimicamente , Adulto JovemRESUMO
ABSTRACT: Suvorexant is a new insomnia drug, and it is generally safe and well tolerated. Here, we report a rare but potentially important adverse effect of suvorexant in a patient with Parkinson disease.
Assuntos
Azepinas/efeitos adversos , Parassonias/induzido quimicamente , Doença de Parkinson/complicações , Medicamentos Indutores do Sono/efeitos adversos , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Triazóis/efeitos adversos , Idoso , Azepinas/uso terapêutico , Sonhos/efeitos dos fármacos , Humanos , Masculino , Parassonias/complicações , Medicamentos Indutores do Sono/uso terapêutico , Triazóis/uso terapêuticoAssuntos
Antipsicóticos/efeitos adversos , Transtornos da Alimentação e da Ingestão de Alimentos/induzido quimicamente , Parassonias/induzido quimicamente , Piperazinas/efeitos adversos , Transtornos Psicóticos/tratamento farmacológico , Tiazóis/efeitos adversos , Adulto , Humanos , Masculino , Sonambulismo/induzido quimicamenteRESUMO
Sleep dysfunction is a pervasive issue in schizophrenia and psychosis. Current knowledge is drawn almost exclusively from studies using quantitative research methodologies that include measures and tools developed in healthy population groups. Qualitative studies investigating the first-person perspectives of sleep problems are therefore important for designing better assessment and treatment tools to meet consumer needs. Focus groups were conducted to elicit detailed information regarding the personal experience of sleep problems, their antecedents and impact, in 14 individuals with schizophrenia-spectrum disorder who experienced insomnia during their illness. Thematic analysis was applied to examine the data and draw treatment implications for sleep management. Insomnia was ubiquitous and frequently co-occurred with other sleep difficulties (nightmares, sleep walking, acting out dreams, etc.) in this group. Discussions revealed themes common across insomnia populations (role of negative mood states and cognitive intrusions) and also new themes on factors contributing to sleep problems in schizophrenia: (1) beliefs that sleep problems cannot be changed; (2) trauma and adversity; (3) lifestyle choices and lack of motivation; and (4) medication side effects. Sleep problems also had profound impact on daytime dysfunctions and disability. The findings point to novel issues that may benefit from consideration in the treatment of sleep problems in schizophrenia. Unhelpful cognitions and behaviours about sleep can be addressed with psychological interventions, activity scheduling and motivational interviewing techniques. Seeking a first-person perspective is vital for identifying issues that will impact on treatment success and recovery.
Assuntos
Atitude Frente a Saúde , Parassonias/psicologia , Esquizofrenia/terapia , Psicologia do Esquizofrênico , Distúrbios do Início e da Manutenção do Sono/psicologia , Adulto , Antipsicóticos/efeitos adversos , Cognição , Terapia Cognitivo-Comportamental , Comorbidade , Feminino , Grupos Focais , Humanos , Estilo de Vida , Masculino , Motivação , Parassonias/induzido quimicamente , Parassonias/terapia , Transtornos Psicóticos/psicologia , Transtornos Psicóticos/terapia , Pesquisa Qualitativa , Distúrbios do Início e da Manutenção do Sono/induzido quimicamente , Distúrbios do Início e da Manutenção do Sono/terapia , Transtornos do Sono-Vigília/induzido quimicamente , Transtornos do Sono-Vigília/psicologia , Transtornos do Sono-Vigília/terapiaAssuntos
Adjuvantes Anestésicos/efeitos adversos , Transtornos da Alimentação e da Ingestão de Alimentos/induzido quimicamente , Parassonias/induzido quimicamente , Oxibato de Sódio/efeitos adversos , Adjuvantes Anestésicos/uso terapêutico , Adulto , Feminino , Humanos , Narcolepsia/tratamento farmacológico , Oxibato de Sódio/uso terapêuticoRESUMO
STUDY OBJECTIVES: To assess adverse drug reaction reports of "abnormal sleep related events" associated with varenicline, a partial agonist to the α4ß2 subtype of nicotinic acetylcholine receptors on neurones, indicated for smoking cessation. DESIGN: Twenty-seven reports of "abnormal sleep related events" often associated with abnormal dreams, nightmares, or somnambulism, which are known to be associated with varenicline use, were identified in the World Health Organisation (WHO) Global Individual Case Safety Reports Database. Original anonymous reports were obtained from the four national pharmacovigilance centers that submitted these reports and assessed for reaction description and causality. MEASUREMENTS AND RESULTS: These 27 reports include 10 of aggressive activity occurring during sleep and seven of other sleep related harmful or potentially harmful activities, such as apparently deliberate self-harm, moving a child or a car, or lighting a stove or a cigarette. Assessment of these 17 reports of aggression or other actual or potential harm showed that nine patients recovered or were recovering on varenicline withdrawal and there were no consistent alternative explanations. Thirteen patients experienced single events, and two had multiple events. Frequency was not stated for the remaining two patients. CONCLUSIONS: The descriptions of the reports of aggression during sleep with violent dreaming are similar to those of rapid eye movement sleep behavior disorder and also nonrapid eye movement (NREM) sleep parasomnias in some adults. Patients who experience somnambulism or dreams of a violent nature while taking varenicline should be advised to consult their health providers. Consideration should be given to clarifying the term sleep disorders in varenicline product information and including sleep related harmful and potentially harmful events.
Assuntos
Agressão/efeitos dos fármacos , Benzazepinas/efeitos adversos , Sonhos/efeitos dos fármacos , Agonistas Nicotínicos/efeitos adversos , Quinoxalinas/efeitos adversos , Transtornos do Sono-Vigília/induzido quimicamente , Adulto , Rotulagem de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Parassonias/induzido quimicamente , Farmacovigilância , Abandono do Hábito de Fumar/psicologia , Sonambulismo/induzido quimicamente , Vareniclina , Organização Mundial da SaúdeRESUMO
Sleep-related eating disorder (SRED) is a condition characterized by recurrent episodes of eating at the transition from night-time sleep to arousal. SRED patients describe eating in an out-of-control manner with preference for high-caloric foods and sometimes with inedible or toxic items. Level of consciousness during SRED episodes ranges from partial consciousness to dense unawareness typical of somnambulistic episodes. SRED is sometimes associated with psychotropic medication, in particular sedative hypnotics, and other sleep disorders, including parasomnias, narcolepsy, and restless legs syndrome. Night eating syndrome (NES) is another important condition in the disordered night-time eating spectrum showing hyperphagia episodes at full arousal from nocturnal sleep without accompanying amnesia. NES could be considered an abnormality in the circadian rhythm of meal timing with a normal circadian timing of sleep onset. The two conditions often overlap and possibly share a common pathophysiology. Studies have suggested that central nervous system serotonin modulation may lead to an effective treatment of NES, while the anti-seizure medication topiramate may be an effective SRED treatment.
Assuntos
Transtornos da Alimentação e da Ingestão de Alimentos/epidemiologia , Hiperfagia/epidemiologia , Transtornos Mentais/epidemiologia , Narcolepsia/epidemiologia , Parassonias/epidemiologia , Síndrome das Pernas Inquietas/epidemiologia , Comorbidade , Transtornos da Alimentação e da Ingestão de Alimentos/induzido quimicamente , Transtornos da Alimentação e da Ingestão de Alimentos/diagnóstico , Transtornos da Alimentação e da Ingestão de Alimentos/fisiopatologia , Humanos , Hiperfagia/induzido quimicamente , Hiperfagia/diagnóstico , Hiperfagia/fisiopatologia , Hipnóticos e Sedativos/efeitos adversos , Parassonias/induzido quimicamente , Parassonias/diagnóstico , Parassonias/fisiopatologiaRESUMO
OBJECTIVE: Complex sleep-related behaviors (CSBs) are often associated with hypnotic use, especially zolpidem. The age effect on the occurrence of CSBs has not been adequately investigated. This study aimed to investigate and compare the clinical correlates of CSBs between adult and elderly subjects who were taking zolpidem. METHOD: A total of 253 adults (aged 20-55 years) and 64 elderly subjects (aged ≥ 65 years) who were administered zolpidem for at least 3 months were enrolled from psychiatric outpatient clinics from June 2011 to May 2012. The sociodemographic characteristics of the participants, the dose of zolpidem, and the occurrence of CSBs were collected. Logistic regression analysis was used to examine the clinical correlates of CSBs. RESULTS: In total, there were 62 members of the adult group (24.5%) and 11 elderly subjects (17.2%) with CSBs; however, the difference did not reach statistical significance. Logistic regression analysis showed that there was a main effect of zolpidem dose (≥ 10 mg; OR = 2.82, P = .038) and alcohol use (OR = 2.05, P = .026), but not sex or age group. There were interactive effects between age group and zolpidem dose (P = .043), indicating that a higher dose of zolpidem was associated with CSBs only in the adult group and not in the elderly group. Adults with CSBs used a higher dose of zolpidem than adults without (mean ± SD: 15.4 ± 6.8 mg vs 11.3 ± 5.7 mg), whereas elderly patients with CSBs did not use a higher dose of zolpidem than those without (12.2 ± 5.4 mg vs 11.9 ± 7.0 mg). CONCLUSIONS: A higher dose of zolpidem was correlated with CSBs only in the adult group and not in the elderly group. Future studies investigating the factors, other than dose, related to CSBs in the elderly will be performed.
Assuntos
Hipnóticos e Sedativos/efeitos adversos , Parassonias/induzido quimicamente , Piridinas/efeitos adversos , Adulto , Fatores Etários , Idoso , Consumo de Bebidas Alcoólicas/efeitos adversos , Feminino , Humanos , Hipnóticos e Sedativos/administração & dosagem , Masculino , Pessoa de Meia-Idade , Piridinas/administração & dosagem , Adulto Jovem , ZolpidemRESUMO
Zolpidem is associated with an amnestic sleep-related eating disorder, but not with compulsive eating behaviors. A 57-year-old woman receiving zolpidem for insomnia showed compulsive evening eating behavior under a wakeful state. Her compulsive evening eating behavior disappeared when zolpidem treatment was halted. Here, we report her case.
Assuntos
Comportamento Compulsivo/induzido quimicamente , Transtornos da Alimentação e da Ingestão de Alimentos/induzido quimicamente , Hipnóticos e Sedativos/efeitos adversos , Parassonias/induzido quimicamente , Piridinas/efeitos adversos , Feminino , Humanos , Pessoa de Meia-Idade , ZolpidemRESUMO
PURPOSE: This study aims to report on catathrenia occurring in narcolepsy with cataplexy (NC) patients under sodium oxybate (SO) treatment. Catathrenia is a parasomnia characterized by groaning and an abnormal respiratory pattern during sleep. METHODS: Fifty-one patients with NC and starting SO therapy underwent a baseline overnight polysomnography (PSG) to detect any sleep-related breathing disorders (SRBD). To avoid risks due to a possible central respiratory control depression by SO, all patients with concomitant obstructive sleep apnea (OSA) were treated with a nasal continuous positive airway pressure (nCPAP) device. After 2 months of treatment with SO, all patients underwent a follow-up overnight PSG to investigate possible newly occurring SRBD. They also underwent a semi-structured clinical interview to monitor other potential SO side effects. RESULTS: At baseline, four out of 51 patients showed simple snoring, and eight, mild to severe OSA. After a titration PSG night, patients with OSA received a nCPAP device. After 2 months of SO treatment, 28 patients (54.9%) showed SO-related side effects, including SRBD in 11 (21.6%). The follow-up PSG showed a respiratory pattern characteristic of catathrenia in seven patients (13.7%) as a newly observed and possibly benign SO side effect, and ruled out a worsening of OSA. CONCLUSIONS: Catathrenia should be considered a possible side effect in NC patients under SO treatment and should be accurately identified to prevent unnecessary SO withdrawal.
Assuntos
Cataplexia/tratamento farmacológico , Depressores do Sistema Nervoso Central/efeitos adversos , Narcolepsia/tratamento farmacológico , Parassonias/induzido quimicamente , Oxibato de Sódio/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Depressores do Sistema Nervoso Central/uso terapêutico , Criança , Terapia Combinada , Comorbidade , Pressão Positiva Contínua nas Vias Aéreas , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Cooperação do Paciente , Polissonografia/efeitos dos fármacos , Apneia Obstrutiva do Sono/tratamento farmacológico , Oxibato de Sódio/uso terapêutico , Adulto JovemRESUMO
Hypnosedative-induced complex behaviors have gained increased attention in recent years as a potential complication of benzodiazepines and benzodiazepine-receptor agonist use. Sodium oxybate (SO), the sodium salt of γ-hydroxybutyrate, an inhibitory neurotransmitter, has been associated with dose-dependent rates of somnambulism; however, there is limited information about complex motor behaviors with SO. We describe a patient with narcolepsy-cataplexy who experienced one episode of sleep-driving and at least two sleep-related eating episodes with therapeutic doses of SO.